Innoviva (INVA) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Innoviva (INVA) do?
Innoviva Inc (INVA) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Collects recurring royalties from GlaxoSmithKline on global respiratory inhaler sales. Sells proprietary antibiotic and cardiovascular treatments directly to hospitals and health systems. Collects respiratory drug royalties from major pharmaceutical partners and sells critical-care hospital treatments. It is worth $1.31B on the market and sold $452.81M over the last year.
- Market cap
- $1.31B
- P/E ratio
- 9.2×
- Annual sales
- $452.81M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 16, 2026
Brands and businesses behind INVA
- Xacduro: Treats hospital-acquired bacterial pneumonia and earns revenue from direct sales to acute care medical centers.
- Giapreza: Increases blood pressure in septic shock patients and earns revenue through hospital pharmaceutical orders.
- Xerava: Treats complicated intra-abdominal bacterial infections in adults, earning revenue from inpatient medical sales.
INVA’s flags, in plain English
Each flag is a number from Innoviva’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 16, 2026.
Stupid Cash
Can pay this year's bills 15.4 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Fat Margins
Profit margin of 42.8%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
Wide Gross Margin
Gross margin of 72.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Growth Cooling
Sales growth slowed to 3.9% a year over 5 years. Sales are growing more slowly than before, which makes the current share price harder to justify.
2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about INVA
How big is Innoviva?
Innoviva’s market cap is $1.31B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $452.81M: what customers paid the company over the last year, before any costs.
What is INVA’s P/E ratio?
INVA’s P/E ratio is 9.2×. Investors pay about 9.2 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with INVA?
A large portion of total cash flow depends on the commercial sales performance of partner GlaxoSmithKline. That is one risk on Innoviva’s card. Its first risk flag is Growth Cooling, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Innoviva’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. INVA’s filings on SEC.gov. The Margin Monkey is research, not advice.
